These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 33047929)

  • 1. Editorial Comment: Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
    Lott F
    Int Braz J Urol; 2021; 47(1):200-201. PubMed ID: 33047929
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone and increased survival in metastatic prostate cancer.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
    [No Abstract]   [Full Text] [Related]  

  • 3. [Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
    Ohlmann CH; Miller K; Gschwend J
    Urologe A; 2017 Sep; 56(9):1185-1186. PubMed ID: 28733874
    [No Abstract]   [Full Text] [Related]  

  • 4. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina C; Messina M; Boccardo F
    Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
    [No Abstract]   [Full Text] [Related]  

  • 5. Abiraterone and increased survival in metastatic prostate cancer.
    Sonpavde G
    N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
    Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
    JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone and castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
    [No Abstract]   [Full Text] [Related]  

  • 8. External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. In Regard to Cho et al.
    Bhattacharyya T; Purushothaman K; Puthiyottil SS; Muttath G
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):719. PubMed ID: 26461012
    [No Abstract]   [Full Text] [Related]  

  • 9. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
    Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 11. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P; Manka L
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line abiraterone improves survival in prostate cancer.
    Brower V
    Lancet Oncol; 2017 Jul; 18(7):e374. PubMed ID: 28602778
    [No Abstract]   [Full Text] [Related]  

  • 15. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
    Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G; Chen X; Gong U; Chen Y; Li G; Wei F; Jiang A; Niu Y; Shang Z
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer: Effectiveness of abiraterone is unaffected by prior ADT.
    Sidaway P
    Nat Rev Urol; 2016 Jan; 13(1):2. PubMed ID: 26553628
    [No Abstract]   [Full Text] [Related]  

  • 20. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
    Aggarwal R
    Eur Urol; 2018 Jun; 73(6):845-846. PubMed ID: 29128209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.